102. ルビンシュタイン・テイビ症候群 ［臨床試験数：3，薬物数：4（DrugBank：1），標的遺伝子数：7，標的パスウェイ数：17］
Searched query = "Rubinstein Taybi syndrome", "RSTS"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04122742 | October 2019 | 22 October 2019 | Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP Variants. | Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP Variants. | Rubinstein-Taybi Syndrome | Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.;Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy;Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations;Other: Functional involvement of identified epigenetic alterations;Biological: Culture of lymphoblastoid line from blood sample | University Hospital, Bordeaux | Not recruiting | 10 Years | N/A | All | 4 | Phase 4 | France | |
| 2 | NCT01619644 | April 2012 | 30 March 2015 | Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial | Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial | Rubinstein-Taybi Syndrome | Drug: sodium valproate;Drug: Placebo | University Hospital, Bordeaux | Fondation Syndrome de Rubinstein-Taybi | Not recruiting | 6 Years | 21 Years | Both | 41 | Phase 2 | France |
| 3 | EUCTR2011-003784-30-FR | 2 October 2017 | Rubinstein-Taybi syndrome: approach to functional imaging and therapeutic trial | Rubinstein-Taybi syndrome: approach to functional imaging and therapeutic trial - RUBIVAL | Rubinstein-Taybi Syndrome MedDRA version: 14.1 Level: PT Classification code 10039281 Term: Rubinstein-Taybi syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Depakine Pharmaceutical Form: Oral liquid Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Buccal use | CHU de bordeaux | Not Available | Female: yes Male: yes | Phase 2 | France |